As a member of Board of Directors at ALBIREO PHARMA INC, Roger A. Jeffs, Ph.D. made $315,035 in total compensation. As a member of Board of Directors at ALBIREO PHARMA INC, Michael Gutch, Ph.D. made $185,084 in total compensation. Cooper is President and CEO of Albireo Pharma, a position to which he was appointed in June 2015. – USA, MA – Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the election of Roger Jeffs, Ph.D., to its board of directors.Dr. Jeffs replaces Denise Scots-Knight, Ph.D., who is departing from the board after nearly 10 years of service. Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and … Albireo Pharma, Inc. (NASDAQ: ALBO) today announced the election of Roger Jeffs, Ph.D., to its board of directors. BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the election of Roger Jeffs, Ph.D., to its board of directors. As a member of Board of Directors at ALBIREO PHARMA INC, David Chiswell, Ph.D. made $195,084 in total compensation. Board of Directors in ALBIREO PHARMA INC. For its 2018 fiscal year, ALBIREO PHARMA INC, listed the following board members on its annual proxy statement to the SEC. Dr. Jeffs replaces Denise Scots-Knight, Ph.D., who is departing from the board after nearly 10 years of service. As a member of Board of Directors at ALBIREO PHARMA INC, Anne Klibanski made $392,848 in total compensation. As a member of Board of Directors at ALBIREO PHARMA, INC., Davey S. Scoon made $181,808 in total compensation. BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the election of Roger Jeffs, Ph.D., to its board of directors. Dr. – USA, MA – Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the election of Anne Klibanski, M.D., and Stephanie Okey, M.S., to its board of directors. (e) On October 10, 2020, the Compensation Committee of the Board of Directors (the "Compensation Committee") of Albireo Pharma, Inc. (the "Company") approved the grant of two contingent cash incentive awards of $100,000 to Martha Carter, Chief Regulatory Officer of the Company, and Patrick T. Horn, M.D., Ph.D., Chief Medical Officer of the Company. Name Total COMPENSATION; Anne Klibanski: Total Cash $392,848: Davey S. Scoon: Total Cash $181,808: David Chiswell, Ph.D. Ron is a life sciences leader with a track record of growing and rejuvenating businesses, brands and organizations – ranging from entrepreneurial, resource-constrained, up to $4.5 billion – … Of this total $21,823 was received as fees earned or paid in cash, $0 was received as non-stock incentive plan compensation, $0 was received as change in pension value and nonqualified deferred compensation earnings, $371,025 was received as options, $0 was awarded as stock and $0 …